Bone Marrow Transplantation in the Treatment of Congenital T Cell Disorders
Bone marrow transplantation (BMT) plays a central role in the management of congenital immunodeficiencies characterized by profound abnormalities of the T cell system [10, 14, 19]. This heterogeneous group of disorders may be corrected by the establishment of a new, donor-dependent immmune system. BMT in these disorders also represents a unique model to study and to define cellular interactions which are operative in the functional reconstitution of the lymphohemopoietic system in man.
KeywordsBone Marrow Transplantation Severe Combine Immunodeficiency Primary Immunodeficiency Disease Adenosine Deaminase Deficiency Congenital Immunodeficiency
Unable to display preview. Download preview PDF.
- 5.Fischer A, Friedrich W, Fasth A, Blanche S et al. (1991) Reduction of graft failure by a monoclonal antibody (anti-LFA-1 CD11a) after HLA nonidentical bone marrow transplantation in children with immunodeficiencies, osteopetrosis and Fanconi’s anemia: a European Group for Immunodeficiency/European Group for Bone Marrow Transplantation Report. Blood 77: 249–256PubMedGoogle Scholar
- 6.Friedrich W, Peter HH, Blütters-Sawatzki R, Ebell W (1986) Analysis of the immunoreconstitution in 19 patients with severe combined immunodeficiency after HLA haploidentical bone-marrow transplantation. In: Vossen J, Griscelli C (eds) Progress in immunodeficiency research and therapy II. Experta Medica, Amsterdam, pp 351–359Google Scholar
- 10.Good RA, Kapoor N, Pahwa RN Wert A, O’Reilly RJ (1980) Current approaches to the primary immunodeficiencies In: Fougereau M, Dausset J (eds) Progress in immunology IV. Academic, LondonGoogle Scholar
- 15.O’Reilly J, Keever CA, Small TN, Brochstein J (1990) The use of HLA-nonidentical T-cell depleted marrow transplants for correction of severe combined immunodeficiency disease. Immunodefic Rev 1: 273–309Google Scholar
- 21.World Health Organization (1983) Primary immunodeficiency disease (Report prepared for the WHO by a scientific group on immunodeficiencies). Clin Immunol Immunpathol 28: 447–450Google Scholar